Oncopeptides AB financials
Oncopeptides AB
549300J9WWQ5CBYQ1M77 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Cost of sales | SEK 2.7M | -SEK 1.1M |
| Gross profit | SEK 29.0M | SEK 36.3M |
| Other income | SEK 6.0M | SEK 5.7M |
| Administrative expenses | SEK 60.8M | SEK 68.9M |
| Operating profit (EBIT) | -SEK 283.5M | -SEK 253.4M |
| Finance costs | SEK 16.6M | SEK 5.8M |
| Profit before tax | -SEK 284.2M | -SEK 248.4M |
| Profit for the year | -SEK 284.6M | -SEK 249.1M |
| Total comprehensive income | -SEK 285.3M | -SEK 249.0M |
| Per share | ||
| Basic EPS | SEK -1.71 | SEK -2.76 |
| Diluted EPS | SEK -1.71 | SEK -2.76 |
| Free cash flow / share | SEK -1.57 | SEK -3.10 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 260.6M | -SEK 279.5M |
| Net cash from investing activities | SEK 496.0K | -SEK 116.0K |
| Purchase of PP&E (capex) | SEK 357.0K | SEK 116.0K |
| Net cash from financing activities | SEK 263.8M | SEK 106.9M |
| Proceeds from borrowings | SEK 0 | SEK 116.0M |
| Lease liability payments | SEK 8.0M | SEK 9.1M |
| Net change in cash | SEK 3.7M | -SEK 172.7M |
| Balance sheet | ||
| Total assets | SEK 244.2M | SEK 238.4M |
| Non-current assets | SEK 27.1M | SEK 35.5M |
| Property, plant & equipment | SEK 6.1M | SEK 8.2M |
| Right-of-use assets | SEK 21.0M | SEK 26.4M |
| Current assets | SEK 217.1M | SEK 202.9M |
| Inventories | SEK 4.4M | SEK 2.4M |
| Trade & other receivables | SEK 7.3M | SEK 2.2M |
| Cash & equivalents | SEK 178.5M | SEK 173.4M |
| Total equity | SEK 54.3M | SEK 56.8M |
| — attributable to owners | SEK 54.3M | SEK 56.8M |
| Non-current liabilities | SEK 138.6M | SEK 136.7M |
| Long-term borrowings | SEK 121.9M | SEK 106.5M |
| Current liabilities | SEK 51.4M | SEK 44.9M |
| Derived metrics | ||
| Free cash flow | -SEK 260.9M | -SEK 279.6M |
| Operating margin | -895.8% | -719.6% |
| Net margin | -899.3% | -707.3% |
| Return on equity | -524.3% | -438.7% |
| Cash conversion ratio | 0.92× | 1.12× |
| Capex coverage | -729.89× | -2409.42× |
| Other reported items | ||
| Additional Paidin Capital | SEK 5.68B | SEK 5.41B |
| Adjustments For Decrease Increase In Inventories | -SEK 1.9M | -SEK 1.3M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -SEK 4.3M | -SEK 16.0M |
| Adjustments For Increase Decrease In Other Current Liabilities | SEK 417.0K | -SEK 25.4M |
| Adjustments For Increase Decrease In Trade Account Payable | SEK 3.1M | -SEK 13.2M |
| Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital | SEK 18.6M | SEK 20.3M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 257.9M | -SEK 223.5M |
| Current Accruals and Current Deferred Income Including Current Contract Liabilities | SEK 11.7M | SEK 15.7M |
| Current Prepaid Expenses | SEK 16.1M | SEK 9.2M |
| Current Tax Expense Income | SEK 562.0K | SEK 664.0K |
| Deferred Tax Expense Income Recognised In Profit Or Loss | SEK 164.0K | SEK 0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 1.4M | SEK 1.6M |
| Equity and Liabilities | SEK 244.2M | SEK 238.4M |
| Finance Income | SEK 15.9M | SEK 10.8M |
| Income Taxes Paid Refund Classified As Operating Activities | -SEK 588.0K | -SEK 1.7M |
| Increase Decrease In Working Capital | SEK 2.7M | SEK 56.0M |
| Increase Decrease Through Exercise of Warrants Equity | — | SEK 0 |
| Increase Decrease Through Sharebased Payment Transactions | SEK 10.9M | SEK 11.5M |
| Increase Decrease Through Transactions With Owners | SEK 282.8M | SEK 11.5M |
| Intangible Assets Other Than Goodwill | SEK 0 | SEK 0 |
| Interest Paid Classified As Operating Activities | SEK 4.0K | SEK 570.0K |
| Interest Received Classified As Operating Activities | SEK 6.4M | SEK 8.6M |
| Issue of Equity | SEK 313.5M | SEK 24.0K |
| Issued Capital | SEK 23.9M | SEK 10.5M |
| Liabilities | SEK 189.9M | SEK 181.6M |
| Noncurrent Financial Assets | SEK 0 | SEK 852.0K |
| Other Comprehensive Income | -SEK 644.0K | SEK 98.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -SEK 644.0K | SEK 98.0K |
| Other Current Liabilities | SEK 21.5M | SEK 14.2M |
| Other Current Receivables | SEK 10.7M | SEK 15.7M |
| Other Noncurrent Liabilities | SEK 16.7M | SEK 30.2M |
| Payments For Share Issue Costs | SEK 41.6M | SEK 0 |
| Proceeds From Issuing Shares | SEK 313.5M | SEK 0 |
| Purchase of Other Longterm Assets Classified As Investing Activities | -SEK 852.0K | SEK 1.0K |
| Purchase of Treasury Shares | — | SEK 24.0K |
| Research and Development Expense | SEK 121.2M | SEK 106.9M |
| Reserve of Exchange Differences On Translation | -SEK 2.8M | -SEK 2.2M |
| Retained Earnings | -SEK 5.65B | -SEK 5.37B |
| Revenue From Contracts With Customers | SEK 31.6M | SEK 35.2M |
| Sales and Marketing Expense | SEK 136.4M | SEK 119.6M |
| Share Issue Related Cost | SEK 41.6M | SEK 0 |
| Trade and Other Current Payables To Trade Suppliers | SEK 18.2M | SEK 15.0M |
Every line item above is a fact tagged in Oncopeptides AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.